Wagg AS, et al. - This article was composed with the goal to compare persistence and adherence with the beta-3-adrenoceptor agonist mirabegron (MIR) vs antimuscarinics (AMs) more than a year. The current study showed that the MIR was related to a significantly longer time to discontinuation, greater persistence and better adherence than AMs. However, there was a steep decline in persistence with all drugs after 1 month. This is unlikely to be wholly explained by anticholinergic adverse events, as it was also seen with MIR. The lower proportion of MIR patients who were treatment-naive reflects current prescribing guidelines whereby MIR is recommended after an initial generic AM trial. Due to the small number of MIR patients, this study was limited.